Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in the EU / 2025-524916-13-00
Authorised, recruiting Phase IV

AIRITY: A hybrid cross-sectional and prospective study to assess patient characteristics, disease burden, disease control, phenotypes, endotypes, and outcomes in a real-world setting in patients with asthma

2025-524916-13-00 · tracked via the Priya Life Science EU tracker
Sponsor type
Pharmaceutical company
Therapeutic area
Respiratory Tract Diseases
Decision date
09/09/2026
Enrollment target
744
Sites
France, Spain, Germany, Italy

Condition studied

Asthma

Investigational medicinal product(s)

BECLOMETASONE

Eligibility

Age group
0-17 years, 18-64 years, 65+ years
Sex
Female, Male

Primary endpoint

1) Asthma control over time, including differences between people with well-controlled and poorly controlled asthma., 2) Changes in asthma treatment use, such as inhalers or other medicines., 3) Changes in lung function over time, based on repeated breathing tests, especially in groups defined by inflammation markers.

Endpoint detail

1) Asthma flare-ups, such as attacks needing extra medication, emergency care, or hospital visits., 2) Use of healthcare services, including doctor visits, emergency visits, and hospital stays., 3) Changes in asthma treatments, such as increases or decreases in medication use., 4) Other health conditions people with asthma may have and how severe they are., 5) Impact on daily life, including sleep quality, fatigue (tiredness), ability to do normal daily activities, and work or school productivity, 6) Patient and doctor views about asthma severity, symptom control, and satisfaction with treatment., 7) Changes in inflammation markers over time and how they relate to asthma symptoms and lung function.

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524916-13-00 on CTIS ↗ ← All trials in the EU